RE:The stock: a tale of friends and foesI think any further big time investment is waiting on midpoint numbers. Reason being is that their previous smaller scale trials that suggest that ACP is 70 or 80% effective are dealing with statistically irrelevant numbers of 10 or 12 people. A meta analysis of random control trials involving autologous stem cell treatment for PAD showed an average of 37% reduction in amputations. Good right?? But a study of blinded placebo random controlled trials saw that efficacy become insignificant. To me that says there is a lot of bias or error in the initial data a lot of producers create. The over 500 patients treated with good results is what is keeping me here and Thomas says he is 98% sure ACP will get to market so thats nice too but the only thing that can scientifically prove it is this phase 2 trial. Scenario 1) ACP proves to be really effective (not sure what endpoint criteria is but assuming we need really good results to end trial early) and we are off to the races. Scenario 2) it proves to be somewhat effective like dozens of previous attempts from other manufacturers and we need another 2 years to enroll more patients and complete the trial. I'm feeling about 50% sure we have a grand slam here. Like Thomas says its all about the data and big money will move if and when we prove we have a winner